TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 174 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $128,441 | -41.5% | 14,367 | +0.5% | 0.00% | -100.0% |
| Q2 2023 | $219,664 | -16.7% | 14,301 | +21.9% | 0.00% | 0.0% |
| Q1 2023 | $263,830 | -5.1% | 11,731 | -11.3% | 0.00% | 0.0% |
| Q4 2022 | $278,143 | -6.7% | 13,226 | +9.4% | 0.00% | 0.0% |
| Q3 2022 | $298,000 | +4.6% | 12,094 | +2.6% | 0.00% | 0.0% |
| Q2 2022 | $285,000 | -37.2% | 11,788 | -33.1% | 0.00% | 0.0% |
| Q1 2022 | $454,000 | -32.1% | 17,632 | -18.1% | 0.00% | 0.0% |
| Q4 2021 | $669,000 | +34.9% | 21,523 | +5.3% | 0.00% | 0.0% |
| Q3 2021 | $496,000 | +30.9% | 20,438 | -21.4% | 0.00% | 0.0% |
| Q2 2021 | $379,000 | -33.3% | 25,987 | +14.2% | 0.00% | -50.0% |
| Q1 2021 | $568,000 | +11.4% | 22,756 | +21.6% | 0.00% | 0.0% |
| Q4 2020 | $510,000 | – | 18,718 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |